Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Nifedipine for Acute Tocolysis of Preterm Labor (Nifedipine)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02132533
Recruitment Status : Completed
First Posted : May 7, 2014
Last Update Posted : February 11, 2019
Sponsor:
Information provided by (Responsible Party):
University of Texas Southwestern Medical Center

Brief Summary:
The purpose of this study is to determine if nifedipine treatment of women in preterm labor receiving corticosteroids results in postponement of delivery when compared to placebo.

Condition or disease Intervention/treatment Phase
Preterm Labor Drug: Nifedipine Drug: Placebo Other: Usual care Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Nifedipine for Acute Tocolysis of Preterm Labor
Actual Study Start Date : May 5, 2014
Actual Primary Completion Date : October 29, 2018
Actual Study Completion Date : October 29, 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Nifedipine

Arm Intervention/treatment
Experimental: Nifedipine
Women with preterm labor will receive nifedipine.
Drug: Nifedipine
Nifedipine 20 mg orally, then nifedipine 20 mg orally after 90 minutes if still contracting. Continue nifedipine 20 mg orally every 4 hours after the first dose for 48 hours.

Other: Usual care
Usual evaluation, monitoring and care for women with preterm labor.

Experimental: Placebo
Women with preterm labor will receive placebo.
Drug: Placebo
Placebo orally, then placebo orally after 90 minutes if still contracting. Continue placebo orally every 4 hours after the first dose for 48 hours.

Other: Usual care
Usual evaluation, monitoring and care for women with preterm labor.




Primary Outcome Measures :
  1. Preterm birth [ Time Frame: Less than 37 weeks of gestation ]

Secondary Outcome Measures :
  1. Preterm birth [ Time Frame: Within 48 hours of randomization ]
  2. At least 2 doses of betamethasone administered [ Time Frame: Prior to delivery ]
  3. Preterm birth [ Time Frame: Within 7 days of randomization ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years to 44 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Between 16 and 44 years of age inclusive
  • Singleton pregnancy
  • Intact membranes
  • Between 28-0/7 weeks and 33-6/7 weeks' gestation inclusive
  • Reported or documented uterine activity
  • Cervical dilation between 2 cm and 4 cm inclusive

Exclusion Criteria:

  • Multifetal gestation
  • Less than 28 weeks' gestation
  • 34 or more weeks' gestation
  • Ruptured membranes
  • More than 4 cm dilated
  • Previously received a course of corticosteroids for fetal lung maturation
  • Oligohydramnios
  • Fetal growth restriction
  • Chorioamnionitis or temperature of at least 38.0 degrees Celsius
  • Fetal death
  • Preeclampsia
  • Suspected placental abruption or placenta previa
  • Lethal fetal malformation or amniotic fluid index at least 35
  • Systolic BP < 90 mmHg or diastolic BP < 50 mmHg
  • Baseline tachycardia (pulse >120 after 2 consecutive measurements 30 minutes apart)
  • Chronic hypertension treated with antihypertensives in pregnancy
  • Seizure disorder or HIV
  • Maternal allergy to nifedipine
  • Known maternal cardiac disease
  • Women who have received progesterone therapy in the second or third trimester for prevention of preterm birth

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02132533


Locations
Layout table for location information
United States, Texas
Parkland Memorial Hospital
Dallas, Texas, United States, 75390
Sponsors and Collaborators
University of Texas Southwestern Medical Center
Investigators
Layout table for investigator information
Study Director: Brian M Casey, MD University of Texas Southwestern Medical Center
Study Director: Donald D McIntire, PhD University of Texas Southwestern Medical Center
Study Director: Kenneth J Leveno, MD University of Texas Southwestern Medical Center
Principal Investigator: Chet Wells, MD University of Texas Southwestern Medical Center

Layout table for additonal information
Responsible Party: University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier: NCT02132533     History of Changes
Other Study ID Numbers: 122013-063
First Posted: May 7, 2014    Key Record Dates
Last Update Posted: February 11, 2019
Last Verified: February 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Premature Birth
Obstetric Labor, Premature
Obstetric Labor Complications
Pregnancy Complications
Nifedipine
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Vasodilator Agents
Tocolytic Agents
Reproductive Control Agents